More than a month has gone by since the last earnings report for Immune Design Corp. . Shares have lost about 6.8% in that time frame, outperforming the market.
Will the recent negative trend continue leading up to the stock's next earnings release, or is it due for a pullback? Before we dive into how investors and analysts have reacted of late, let's take a quick look at its most recent earnings report in order to get a better handle on the important catalysts.
Immune Design Posts Narrower-than-Expected Loss in Q2
Immune Design incurred second-quarter 2017 loss of 54 cents per share, narrower than the Zacks Consensus Estimate of a loss of 65 cents and also a year-ago loss of 71 cents.
Quarter in Detail
Immune Design’s total revenue for the second quarter was $0.7 million, down from $1.1 million in the year ago quarter. The revenue was primarily due to $0.7 million collaboration revenue received from partner Sanofi for G103 (HSV2 therapeutic vaccine). Quarterly revenues were below the Zacks Consensus Estimate of $2 million.
Research and development (R&D) expenses were down 4.6% to $10.9 million in the quarter. The decrease was due to the timing differences of manufacturing activities, which were offset by increased clinical costs attributable to continued advancement of Immune Design’s phase I and phase II studies, and an increase in personnel-related expenses that are needed to support the company’s pipeline.
General and administrative expenses also decreased 1.5% to $3.9 million.
Pipeline Update
Immune Design is developing multiple candidates using its two discovery platforms – ZVex and GLAAS – in the field of immuno-oncology. Its key pipeline candidates include CMB305 and G100.
Presently, CMB305 is being evaluated in soft tissue sarcoma (STS) patients both as monotherapy and in combination with an anti-PD-L1 antibody. The company presented CMB305 monotherapy data pat ASCO from 25 STS patients with recurrent disease. The data showed that observed median overall survival (mOS) has not yet been reached in these patients, with an overall survival rate at 12 and 18 months of 83% and 76%, respectively.
Furthermore, G100, which is developed on the GLAAS platform, is being evaluated in an ongoing phase I dose escalation and in a randomized phase II study in patients with low grade follicular non-Hodgkin lymphoma (NHL). The data from the phase I dose escalation monotherapy study presented at ASCO demonstrated-100% disease control rate (DCR), with over a third of patients achieving a partial response (PR) using WHO criteria (at least a 50% tumor reduction), with PRs at all three dose levels tested. 50% of evaluable patients experienced shrinkage of untreated distal (abscopal) lesions in association with presence of T cell infiltrates.
Notably, Immune Design completed patient enrolment in the phase II study comparing G100 and low dose radiation (XRT) versus G100 and XRT with the systemic administration of Merck & Co., Inc.’s anti-PD-1 agent, Keytruda. The company intends to submit data from all 24 patients in the randomized phase II study comparing G100 and XRT versus G100 and XRT with pembrolizumab in Dec 2017. Furthermore, it also plans to submit follow-up data from all patients treated with G100 monotherapy in the phase I dose escalation portion of this study.
2017 Outlook
Immune Design continues to anticipate cash to fund operations into the second half of 2018.
How Have Estimates Been Moving Since Then?
In the past month, investors have witnessed a downward trend in fresh estimates. There has one revision lower for the current quarter.
Immune Design Corp. Price and Consensus
VGM Scores
At this time, Immune Design's stock has a nice Growth Score of B, a grade with the same score on the momentum front. The stock was allocated a grade of F on the value side, putting it in the fifth quintile for this investment strategy.
Overall, the stock has an aggregate VGM Score of D. If you aren't focused on one strategy, this score is the one you should be interested in.
The company's stock is suitable for growth and momentum investors based on our style scores.
Outlook
Estimates have been broadly trending downward for the stock. The magnitude of this revision also indicates a downward shift. Notably, the stock has a Zacks Rank #3 (Hold). We expect in-line returns from the stock in the next few months.
Image: Bigstock
Why Is Immune Design (IMDZ) Down 6.8% Since the Last Earnings Report?
More than a month has gone by since the last earnings report for Immune Design Corp. . Shares have lost about 6.8% in that time frame, outperforming the market.
Will the recent negative trend continue leading up to the stock's next earnings release, or is it due for a pullback? Before we dive into how investors and analysts have reacted of late, let's take a quick look at its most recent earnings report in order to get a better handle on the important catalysts.
Immune Design Posts Narrower-than-Expected Loss in Q2
Immune Design incurred second-quarter 2017 loss of 54 cents per share, narrower than the Zacks Consensus Estimate of a loss of 65 cents and also a year-ago loss of 71 cents.
Quarter in Detail
Immune Design’s total revenue for the second quarter was $0.7 million, down from $1.1 million in the year ago quarter. The revenue was primarily due to $0.7 million collaboration revenue received from partner Sanofi for G103 (HSV2 therapeutic vaccine). Quarterly revenues were below the Zacks Consensus Estimate of $2 million.
Research and development (R&D) expenses were down 4.6% to $10.9 million in the quarter. The decrease was due to the timing differences of manufacturing activities, which were offset by increased clinical costs attributable to continued advancement of Immune Design’s phase I and phase II studies, and an increase in personnel-related expenses that are needed to support the company’s pipeline.
General and administrative expenses also decreased 1.5% to $3.9 million.
Pipeline Update
Immune Design is developing multiple candidates using its two discovery platforms – ZVex and GLAAS – in the field of immuno-oncology. Its key pipeline candidates include CMB305 and G100.
Presently, CMB305 is being evaluated in soft tissue sarcoma (STS) patients both as monotherapy and in combination with an anti-PD-L1 antibody. The company presented CMB305 monotherapy data pat ASCO from 25 STS patients with recurrent disease. The data showed that observed median overall survival (mOS) has not yet been reached in these patients, with an overall survival rate at 12 and 18 months of 83% and 76%, respectively.
Furthermore, G100, which is developed on the GLAAS platform, is being evaluated in an ongoing phase I dose escalation and in a randomized phase II study in patients with low grade follicular non-Hodgkin lymphoma (NHL). The data from the phase I dose escalation monotherapy study presented at ASCO demonstrated-100% disease control rate (DCR), with over a third of patients achieving a partial response (PR) using WHO criteria (at least a 50% tumor reduction), with PRs at all three dose levels tested. 50% of evaluable patients experienced shrinkage of untreated distal (abscopal) lesions in association with presence of T cell infiltrates.
Notably, Immune Design completed patient enrolment in the phase II study comparing G100 and low dose radiation (XRT) versus G100 and XRT with the systemic administration of Merck & Co., Inc.’s anti-PD-1 agent, Keytruda. The company intends to submit data from all 24 patients in the randomized phase II study comparing G100 and XRT versus G100 and XRT with pembrolizumab in Dec 2017. Furthermore, it also plans to submit follow-up data from all patients treated with G100 monotherapy in the phase I dose escalation portion of this study.
2017 Outlook
Immune Design continues to anticipate cash to fund operations into the second half of 2018.
How Have Estimates Been Moving Since Then?
In the past month, investors have witnessed a downward trend in fresh estimates. There has one revision lower for the current quarter.
Immune Design Corp. Price and Consensus
Immune Design Corp. Price and Consensus | Immune Design Corp. Quote
VGM Scores
At this time, Immune Design's stock has a nice Growth Score of B, a grade with the same score on the momentum front. The stock was allocated a grade of F on the value side, putting it in the fifth quintile for this investment strategy.
Overall, the stock has an aggregate VGM Score of D. If you aren't focused on one strategy, this score is the one you should be interested in.
The company's stock is suitable for growth and momentum investors based on our style scores.
Outlook
Estimates have been broadly trending downward for the stock. The magnitude of this revision also indicates a downward shift. Notably, the stock has a Zacks Rank #3 (Hold). We expect in-line returns from the stock in the next few months.